flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer [clinicaltrials:NCT00019396]
flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer [clinicaltrials:NCT00019396]
Bio2RDF identifier
NCT00019396
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00019396
identifiers.org URI
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
RATIONALE: The drug flt ...... elanoma or renal cell cancer.
brief title [clinicaltrials_vocabulary:brief-title]
flt3L With or Without Vaccine ...... Melanoma or Renal Cell Cancer
completion date [clinicaltrials_vocabulary:completion-date]
2007-03-01T00:00:00Z
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
OBJECTIVES: I. Evaluate ...... study
within 16 months.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
2007-03-01T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
keyword [clinicaltrials_vocabulary:keyword]
adult solid tumor
body system/site cancer
kidney tumor
kidney/urinary cancer
recurrent melanoma
recurrent renal cell cancer
renal cell cancer
skin tumor
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2013-06-19T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
location [clinicaltrials_vocabulary:location]
nct alias [clinicaltrials_vocabulary:nct-alias]
NCT00001687
nct id [clinicaltrials_vocabulary:nct-id]
NCT00019396
official title [clinicaltrials_vocabulary:official-title]
Phase II Study of Flt3 Ligand ...... Melanoma or Renal Cell Cancer
org study id [clinicaltrials_vocabulary:org-study-id]
CDR0000065997
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
secondary id [clinicaltrials_vocabulary:secondary-id]
NCI-98-C-0040
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
1998-02-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2006-05-01T00:00:00Z
identifier
clinicaltrials:NCT00019396
title
flt3L With or Without Vaccine ...... Melanoma or Renal Cell Cancer
@en
type
label
flt3L With or Without Vaccine ...... r [clinicaltrials:NCT00019396]
@en